Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)

3 years ago

IRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the…

Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

3 years ago

First endocrine innovation in more than 20 years which has shown improved efficacy over standard-of-care treatments in patients with advanced breast…

KemPharm Enhances Senior Management Team

3 years ago

Daniel Gallo, Ph.D., Appointed Senior Vice President of Medical Affairs and Advocacy Abbi Maher, J.D., Named Vice President of Legal…

Microbot Medical Welcomes Distinguished Interventional Cardiologist and Early Adopter of Endovascular Robotics to its Next “Access-Ability Live by MBOT” Webinar Series

3 years ago

Dr. Giora Weisz, a Practicing Interventional Cardiologist and Clinical Researcher who was One of the Early Users of Robotic-Enhanced Coronary…

Medicenna to Present at the 2023 Guggenheim Oncology Conference

3 years ago

TORONTO and HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage…

Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant Cancers

3 years ago

Development expected to capitalize upon tumor targeting Quatramers™ MUC1-C could be effective against a number of drug resistant cancers such…

SmileDirectClub to Report Fourth Quarter and Year End 2022 Results on February 28, 2023

3 years ago

NASHVILLE, Tenn., Jan. 30, 2023 (GLOBE NEWSWIRE) -- SmileDirectClub, Inc. (Nasdaq: SDC), the next generation oral care company with the…

GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery

3 years ago

Company submitted nearly one quarter of all candidate gene submissions to GeneMatcher in 2022 and collaborated on 63 publications involving…

Anti-Bb Antibody (NM8074) Receives US FDA Clearance to Start Clinical Trial in Naïve aHUS Patients (Rare Disease)

3 years ago

-- FDA Clears Initiation of Efficacy Trial in aHUS (Atypical Hemolytic Uremic Syndrome) Patients An Efficacy Trial in Adult aHUS…

QHSLab, Inc. Reiterates its 2022 Projection of a $7.5 Billion Addressable Market for its Integrated Service Program (ISP) Digital Health Solution Designed For Primary Care

3 years ago

QHSLab reports that commercialization and the path to profitability is in clear sight, which is an unfamiliar acknowledgment for investors…